Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Decline in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 400,700 shares, a decline of 7.9% from the October 31st total of 434,900 shares. Currently, 2.5% of the shares of the company are short sold. Based on an average trading volume of 126,100 shares, the short-interest ratio is currently 3.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC bought a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned approximately 0.10% of Immix Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 11.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Immix Biopharma in a research note on Thursday, October 3rd.

Immix Biopharma Price Performance

Shares of NASDAQ:IMMX traded down $0.10 during trading hours on Monday, hitting $2.01. The company’s stock had a trading volume of 264,533 shares, compared to its average volume of 182,827. Immix Biopharma has a 52 week low of $1.26 and a 52 week high of $7.75. The company has a market capitalization of $55.29 million, a price-to-earnings ratio of -2.38 and a beta of 0.11. The firm’s fifty day moving average price is $1.63 and its 200 day moving average price is $1.93.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). On average, equities research analysts predict that Immix Biopharma will post -0.64 earnings per share for the current fiscal year.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.